Skip to main content

Welkom bij Erasmus MC & Bohn Stafleu van Loghum

Erasmus MC heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Registreer

Om ook buiten de locaties van Erasmus MC, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van Erasmus MC.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top

2015 | OriginalPaper | Hoofdstuk

Hoofdstuk 9 (Farmaco)therapie van diabetes mellitus type 2 bij de oudere patiënt

Auteur : R. Holtrop

Gepubliceerd in: De oudere patiënt met diabetes mellitus type 2

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

In de United Kingdom Prospective Diabetes Study (UKPDS, 1998) werden circa 4000 patiënten vervolgd, bij wie recent de diagnose diabetes mellitus type 2 was gesteld. De gemiddelde leeftijd van de deelnemers was 53 jaar, de helft van de mensen had overgewicht en 40% had hypertensie. De gemiddelde nuchtere glucose voorafgaand aan de start van de studie was 11,9 mmol/L. Aan het begin van de studie kregen de deelnemers als eerste een dieet. Als vervolgens na verloop van tijd de bloedglucose weer opliep, werd de behandeling aangepast. De patiënten werden at random toegewezen aan:
Literatuur
go back to reference Bode B, et al. Efficacy and safety of canaglifozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013;41:72–8.CrossRef Bode B, et al. Efficacy and safety of canaglifozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013;41:72–8.CrossRef
go back to reference Bourdel-Marchasson 1, et al. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract 2011;39:7–21.CrossRef Bourdel-Marchasson 1, et al. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract 2011;39:7–21.CrossRef
go back to reference Doucet J, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetic elderly patients. Geriatr Psychol Neuropsychiatr Vieil 2011;9(2):157–62.PubMed Doucet J, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetic elderly patients. Geriatr Psychol Neuropsychiatr Vieil 2011;9(2):157–62.PubMed
go back to reference Haas L. Management of diabetes mellitus medications in the nursing home. Drugs Aging 2005;22:209–18.CrossRefPubMed Haas L. Management of diabetes mellitus medications in the nursing home. Drugs Aging 2005;22:209–18.CrossRefPubMed
go back to reference Holstein A, et al. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatrie patients. Expert Opin Drug Saf 2010;9(5):675–81.CrossRefPubMed Holstein A, et al. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatrie patients. Expert Opin Drug Saf 2010;9(5):675–81.CrossRefPubMed
go back to reference Knowler WC, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.CrossRefPubMed Knowler WC, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.CrossRefPubMed
go back to reference Lakey WC, et al. Are current clinical trials in diabetes addressing important issues in diabetes care? Diabetologia 2013;56:1226–35.CrossRefPubMed Lakey WC, et al. Are current clinical trials in diabetes addressing important issues in diabetes care? Diabetologia 2013;56:1226–35.CrossRefPubMed
go back to reference Lechleitner M. Oral antidiabetic dmg therapy in type 2 diabetes mellitus – focus on elderly patients. Wien Med Wochenschr 2011;161(11–12):297–9.CrossRefPubMed Lechleitner M. Oral antidiabetic dmg therapy in type 2 diabetes mellitus – focus on elderly patients. Wien Med Wochenschr 2011;161(11–12):297–9.CrossRefPubMed
go back to reference Mutasingwa DR, et al. How applicable are clinical practice guidelines to elderly patients with comorbidities? Can Fam Physician 2011:57:253–62. Mutasingwa DR, et al. How applicable are clinical practice guidelines to elderly patients with comorbidities? Can Fam Physician 2011:57:253–62.
go back to reference Nathan DM, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963–72.CrossRefPubMed Nathan DM, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963–72.CrossRefPubMed
go back to reference Neumiller JJ, et al. Pharmacologic management of the older patiënt with type 2 diabetes. Am J Geriatr Pharmacother 2009;7(6):324–42.CrossRefPubMed Neumiller JJ, et al. Pharmacologic management of the older patiënt with type 2 diabetes. Am J Geriatr Pharmacother 2009;7(6):324–42.CrossRefPubMed
go back to reference Paolisso G, et al. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther 2012; 29(3):218–33.CrossRefPubMed Paolisso G, et al. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther 2012; 29(3):218–33.CrossRefPubMed
go back to reference Rojas LB, et al. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013:5:1–15.CrossRef Rojas LB, et al. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013:5:1–15.CrossRef
go back to reference Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49(9):573–88.CrossRefPubMed Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49(9):573–88.CrossRefPubMed
go back to reference Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8(5):405–18.CrossRefPubMed Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8(5):405–18.CrossRefPubMed
go back to reference Sinclair AJ. Aging and diabetes mellitus. In: International Textbook of Diabetes mellitus. DeFronzo R, et al. (eds.), 2004. Sinclair AJ. Aging and diabetes mellitus. In: International Textbook of Diabetes mellitus. DeFronzo R, et al. (eds.), 2004.
go back to reference Skarforst ET, et al. Physical training as treatment for type 2 diabetes (non-insulin-dependent) diabetes in elderly men: a feasibility study over 2 years. Diabetologia 1987;30:930–3.CrossRef Skarforst ET, et al. Physical training as treatment for type 2 diabetes (non-insulin-dependent) diabetes in elderly men: a feasibility study over 2 years. Diabetologia 1987;30:930–3.CrossRef
go back to reference Yehuda AB, Zinger A, Durso S. The older patient with diabetes: a practical approach. Diabetes Metab Res Rev 2014;30:8895Yki-Jarvinnen H, Dressler A, Ziemen M; HOE 901/300S Study Group. Les nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glagine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130–6. Yehuda AB, Zinger A, Durso S. The older patient with diabetes: a practical approach. Diabetes Metab Res Rev 2014;30:8895Yki-Jarvinnen H, Dressler A, Ziemen M; HOE 901/300S Study Group. Les nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glagine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130–6.
Metagegevens
Titel
Hoofdstuk 9 (Farmaco)therapie van diabetes mellitus type 2 bij de oudere patiënt
Auteur
R. Holtrop
Copyright
2015
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-0727-2_9